(2S,4S)-4-Mercapto-2-[(3S)-3-(4-nitrobenzyloxycarbonyl)aminopyrrolidin-1-ylcarbonyl]-1-methylpyrrolidine | 147081-82-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4S)-4-Mercapto-2-[(3S)-3-(4-nitrobenzyloxycarbonyl)aminopyrrolidin-1-ylcarbonyl]-1-methylpyrrolidine
• 英文别名: (4-nitrophenyl)methyl N-[(3S)-1-[(2S,4S)-1-methyl-4-sulfanylpyrrolidine-2-carbonyl]pyrrolidin-3-yl]carbamate
• CAS: 147081-82-1
• 化学式: C₁₈H₂₄N₄O₅S
• 分子量: 408.478
• InChiKey: UFMYCNWNDBMWNK-BPUTZDHNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (2S,4S)-4-Mercapto-2-[(3S)-3-(4-nitrobenzyloxycarbonyl)aminopyrrolidin-1-ylcarbonyl]-1-methylpyrrolidine 在 palladium on activated charcoal 氢气 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 生成 (4R,5S,6S)-3-[(3S,5S)-5-[(3S)-3-aminopyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
  参考文献：
  名称：

  Synthesis and Antibacterial Activity of Novel 1.BETA.-Methyl Carbapenems with Cycloalkylamine Moiety at the C-2 Position.

  摘要：

  具有环烷基胺侧链的新型1β-甲基碳青霉烯类化合物被合成，并研究了它们的构效关系。这些碳青霉烯类化合物对广泛的革兰氏阳性和革兰氏阴性细菌展现出强大的抗菌活性，并且在小鼠腹腔给药时具有中等程度的尿液回收率。

  DOI：

  10.7164/antibiotics.54.1080
• 作为产物：
  描述：

  氯甲酸对硝基苄酯 在 三氟甲磺酸 、 苯甲醚 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 三氟乙酸 为溶剂， 生成 (2S,4S)-4-Mercapto-2-[(3S)-3-(4-nitrobenzyloxycarbonyl)aminopyrrolidin-1-ylcarbonyl]-1-methylpyrrolidine
  参考文献：
  名称：

  Synthesis and Antibacterial Activity of Novel 1.BETA.-Methyl Carbapenems with Cycloalkylamine Moiety at the C-2 Position.

  摘要：

  具有环烷基胺侧链的新型1β-甲基碳青霉烯类化合物被合成，并研究了它们的构效关系。这些碳青霉烯类化合物对广泛的革兰氏阳性和革兰氏阴性细菌展现出强大的抗菌活性，并且在小鼠腹腔给药时具有中等程度的尿液回收率。

  DOI：

  10.7164/antibiotics.54.1080

文献信息

• Metal catalyzed displacement process
  申请人：Sankyo Company, Limited

  公开号：US05681951A1

  公开（公告）日：1997-10-28

  A process for preparing a compound of formula (I'): ##STR1## comprising reacting a compound of formula (II'): ##STR2## with a compound of formula (III'): A'SH (III') wherein the reaction of the compound of formula (II') and the compound of formula (III') are carried out in the presence of a salt of a metal of Group II or III of the Periodic Table of Elements, wherein A' is an alkyl, aryl, aralkyl or heterocyclic, R.sup.1' is hydrogen or a carboxy protecting group, R.sup.2' and R.sup.3' can be hydrogen or alkyl, X' can be sulfur, k' is 1 or 2 and R.sup.4' is alkyl, alkenyl, aryl, aralkyl, cycloalkyl or heterocyclic.

  一种制备式（I'）化合物的方法： ##STR1## 包括将式（II'）化合物与式（III'）化合物反应： ##STR2## 其中化合物（II'）和化合物（III'）的反应在元素周期表II或III族金属的盐的存在下进行，其中A'是烷基，芳基，芳烷基或杂环基，R.sup.1'是氢或羧基保护基，R.sup.2'和R.sup.3'可以是氢或烷基，X'可以是硫，k'为1或2，R.sup.4'是烷基，烯基，芳基，芳烷基，环烷基或杂环基。
• Azetidinone compounds useful in the preparation of carbapenem
  申请人：Sankyo Company, Limited

  公开号：US05541317A1

  公开（公告）日：1996-07-30

  Compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen or a hydroxy-protecting group; R.sup.2 is alkyl, alkoxy, halogen, optionally substituted phenyl or optionally substituted phenoxy; R.sup.3 is optionally substituted pyridyl, optionally substituted quinolyl or phenyl group which has a substituent of formula --CYNR.sup.5 R.sup.6, where Y is oxygen or sulfur, and R.sup.5 and R.sup.6 are each alkyl, aryl or aralkyl, or R.sup.5 and R.sup.6 and the nitrogen to which they are attached together form a heterocyclic group; is R.sup.4 hydrogen or an amino-protecting group; and Z is sulfur or oxygen; are valuable intermediates in the preparation of carbapenem compounds and retain a desirable configuration during conversion to such carbapenem compounds. Penem and carbapenem compounds having a group of formula --SA' are prepared from a corresponding compound having a substituted thio, sulfinyl or sulfonyl group at this position by reaction with a compound A'SH (where A' is an organic group) in the presence of a salt of a metal of Group II or III of the Periodic Table.

  化合物的式子(I)：##STR1## 其中：R.sup.1为氢或羟基保护基；R.sup.2为烷基，烷氧基，卤素，可选择取代的苯基或可选择取代的苯氧基；R.sup.3为可选择取代的吡啶基，可选择取代的喹啉基或具有式子--CYNR.sup.5 R.sup.6的取代基的苯基，其中Y为氧或硫，而R.sup.5和R.sup.6均为烷基，芳基或芳基烷基，或R.sup.5和R.sup.6以及它们所连接的氮共同形成一个杂环基团；R.sup.4为氢或氨基保护基；Z为硫或氧；是制备碳青霉烯化合物的有价值的中间体，并在转化为碳青霉烯化合物期间保持理想的构型。具有式子--SA'的青霉烯和碳青霉烯化合物是通过与具有该位置的取代硫，亚砜或磺酰基的相应化合物在周期表第二或第三组金属的盐存在下与化合物A'SH（其中A'是有机基团）反应制备的。
• Silyl enol ether alkylation process
  申请人：Sankyo Company, Limited

  公开号：US05719275A1

  公开（公告）日：1998-02-17

  A method for preparing compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen or a hydroxy-protecting group; R.sup.2 is alkyl, alkoxy, halogen, optionally substituted phenyl or optionally substituted phenoxy; R.sup.3 is optionally substituted pyridyl, optionally substituted quinolyl or phenyl group which has a substituent of formula --CYNR.sup.5 R.sup.6, where Y is oxygen or sulfur, and R.sup.5 and R.sup.6 are each alkyl, aryl or aralkyl, or R.sup.5 and R.sup.6 and the nitrogen to which they are attached together form a heterocyclic group; R.sup.4 is hydrogen or an amino-protecting group; and Z is sulfur or oxygen. The process comprises reacting a compound of formula (II): ##STR2## in which R.sup.8, R.sup.9 and R.sup.10 are the same or different and each represents an alkyl group having from 1 to 4 carbon atoms or a phenyl group, with a compound of formula (III): ##STR3## in which R.sup.11 represents an acyloxy, alkylsulfonyl, arylsulfonyl, alkylsulfinyl or arylsulfinyl group.

  一种制备式（I）化合物的方法：其中：R.sup.1是氢或羟基保护基；R.sup.2是烷基，烷氧基，卤素，可选地取代的苯基或可选地取代的苯氧基；R.sup.3是可选地取代的吡啶基，可选地取代的喹啉基或具有式--CYNR.sup.5 R.sup.6的取代基的苯基，其中Y是氧或硫，R.sup.5和R.sup.6分别是烷基，芳基或芳烷基，或R.sup.5和R.sup.6和它们所连接的氮共同形成一个杂环基；R.sup.4是氢或氨基保护基；Z是硫或氧。该过程包括将式（II）的化合物与式（III）的化合物反应：其中R.sup.8，R.sup.9和R.sup.10相同或不同，每个代表具有1至4个碳原子的烷基或苯基。其中，式（II）为：##STR2##式（III）为：##STR3##
• Carbapenem derivatives, their preparation and their use as antibiotics
  申请人：Sankyo Company, Limited

  公开号：US05866564A1

  公开（公告）日：1999-02-02

  Compound of formula (I): ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl or --C(.dbd.NH)R.sup.0 where R.sup.0 is hydrogen or C.sub.1 -C.sub.6 alkyl; A is ##STR2## R.sup.2 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl or --C(.dbd.NH)R.sup.6 where R.sup.6 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.3 -C.sub.7 cycloalkyl; R.sup.3 and R.sup.4 are independently hydrogen, C.sub.1 -C.sub.6 alkyl, halogen, hydroxy, carboxy, cyano, --CO.NR.sup.a R.sup.b, --OCO.NR.sup.a R.sup.b or --NR.sup.a R.sup.b, where R.sup.a and R.sup.b are independently hydrogen or C.sub.1 -C.sub.6 alkyl; R.sup.20", R.sup.21', and R.sup.22" are independently hydrogen or C.sub.1 -C.sub.6 alkyl or R.sup.20" and R.sup.21" or R.sup.20" and R.sup.22" together form a heterocyclic group; R.sup.23" and R.sup.24" are independently hydrogen, halogen or C.sub.1 -C.sub.6 alkyl; n is 1, 2 or 3; and n.sup.3" is 1, 2 or 3. The compounds are antibiotics which are resistant to dehydropeptidase I, and are useful for the treatment of microbial infections.

  化合物的公式（I）：##STR1## 其中R.sup.1是氢，C.sub.1-C.sub.6烷基，C.sub.2-C.sub.6烯基，C.sub.2-C.sub.6炔基或--C(.dbd.NH)R.sup.0，其中R.sup.0是氢或C.sub.1-C.sub.6烷基; A是##STR2## R.sup.2是氢，C.sub.1-C.sub.6烷基，C.sub.2-C.sub.6烯基，C.sub.2-C.sub.6炔基或--C(.dbd.NH)R.sup.6，其中R.sup.6是氢，C.sub.1-C.sub.6烷基或C.sub.3-C.sub.7环烷基; R.sup.3和R.sup.4独立地是氢，C.sub.1-C.sub.6烷基，卤素，羟基，羧基，氰基，--CO.NR.sup.aR.sup.b，--OCO.NR.sup.aR.sup.b或--NR.sup.aR.sup.b，其中R.sup.a和R.sup.b独立地是氢或C.sub.1-C.sub.6烷基; R.sup.20"，R.sup.21'和R.sup.22"独立地是氢或C.sub.1-C.sub.6烷基，或R.sup.20"和R.sup.21"或R.sup.20"和R.sup.22"一起形成一个杂环基团; R.sup.23"和R.sup.24"独立地是氢，卤素或C.sub.1-C.sub.6烷基; n为1, 2或3; n.sup.3"为1, 2或3。这些化合物是对去氢肽酶I具有抗性的抗生素，可用于治疗微生物感染。
• Somatotropins with alterations in the alpha-helix 3 region, alpha-helix 2 region combinations thereof, and in combination with other mutations
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0488279A2

  公开（公告）日：1992-06-03

  The present invention relates to somatotropin analogues with amino acid changes in the α-helix 3 regions of said somatotropins, changes in the α-helix 2 regions, combinations thereof plus combinations with other changes to the native amino acid sequence of somatotropins. The resulting analogues are stable for formulation in sustained release formulations, while maintaining biological activity. Further, methods for conducting site-directed mutagenesis on DNA encoding proteins and/or polypeptides also are provided.

  本发明涉及在所述促体液素的α-螺旋 3 区氨基酸发生变化、α-螺旋 2 区发生变化、其组合以及与促体液素原生氨基酸序列的其他变化组合的促体液素类似物。由此产生的类似物可稳定地配制成缓释制剂，同时保持生物活性。此外，还提供了对编码蛋白质和/或多肽的 DNA 进行定点诱变的方法。